Skip to main content
OpenTrials
Completed

NCT Number: NCT00572403

Risk Factors Contributing to the Development of Microalbuminuria

This research project will look at the relationship between baseline variables, and the new onset of microalbuminuria and the response to treatment with an angiotensin receptor blocker, losartan, in a cohort of 246 early hypertensives and normotensives who are being brought back for a 4-5 year follow up visit as part of a continuing project. We hypothesize that the new onset of microalbuminuria is associated with higher blood pressure levels at baseline and 1 year as well as being associated with elevated left ventricular mass index. The rate of new onset microalbuminuria in non-diabetics is not established and this prospective study will provide data.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Microalbuminuria

Age range

45 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N3M5, Canada

About this study

The primary objective of this research project is to determine risk factors related to the development of microalbuminuria. The secondary objective is to determine whether uric acid levels at the final visit are correlated with the onset of microalbuminuria. Of participants returning for a 4-5 year follow up visit as part of a continuing project, we will examine the proportion that have developed microalbuminuria. Subjects found to have microalbuminuria will be offered therapy with the ARB losartan and will be followed at three months to determine if there has been a reduction in levels.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • participation in the Double Exposure study
  • elevated microalbuminuria

Treatment and study plan

Primary outcomes

  1. To determine risk factors related to the development of microalbuminuria.

    Time frame: 3 months

Secondary outcomes

  1. To determine whether uric acid levels at the final visit are correlated with the onset of microalbuminuria.

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Sunnybrook Health Sciences Centre

Other

Collaborators

  • Merck Frosst Canada Ltd.

Registry information

Official study title

Risk Factors Contributing to the Development of Microalbuminuria Over a 5 Year Period

Important dates

Study start
2007
Study completion
2008
First posted
Dec 13, 2007
Registry last updated
Mar 8, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.